Art. -Nr.: HY-136657

SC-43

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.01%
CAS. Nr.: 1400989-25-4
Formel: C₂₁H₁₃ClF₃N₃O₂
Molecular Weight:431.80

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

SC-43 Chemical Structure

CAS. Nr.: 1400989-25-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

SHP-1

p-STAT3

Alle STAT Isoform-spezifische Produkte anzeigen :

In Vitro

SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively^[1].
SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment shows increased sub-G1 cells and G2-M arrest, indicating SC-43 induced differential apoptotic effects in these cell lines^[1].
SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment demonstrates significant increase in cleaved caspase-3 and PARP level^[1].
SC-43 activates SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation. SC-43 augments SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HuCCT-1, KKU-100, and CGCCA cells
Concentration:

0 μM, 0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time:

24 hours, 48 hours, 72 hours
Result:

Revealed the anti-proliferative effects in CCA cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively.

Cell Cycle Analysis^[1]

Cell Line:

HuCCT-1, KKU-100, and CGCCA cells
Concentration:

0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time:

24 hours
Result:

Showed increased sub-G1 cells and G2-M arrest.

Western Blot Analysis^[1]

Cell Line:

HuCCT-1, KKU-100, and CGCCA cells
Concentration:

0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time:

24 hours
Result:

Demonstrated significant increase in cleaved caspase-3 and PARP level.

In Vivo

SC-43 (10-30 mg/kg; oral gavage; daily; for 23 days; male NCr athymic nude mice) treatment exhibits xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male NCr athymic nude mice (5-7 weeks of age) injected with HuCCT-1 cells^[1]
Dosage:

10 mg/kg or 30 mg/kg
Administration:

Oral gavage; daily; for 23 days
Result:

Exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1400989-25-4
Appearance Solid
Molecular Weight 431.80
Formel C₂₁H₁₃ClF₃N₃O₂
Color White to off-white
SMILES

O=C(NC1=CC=CC(OC2=CC=C(C#N)C=C2)=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayHistological Imaging/StainingELISABio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Branched-chain amino acids alleviate sepsis-induced myocardial dysfunction via inhibition of protein tyrosine phosphatase-6. [Abstract]

2025 Apr 30;10(1):135. PMID: 40301312
Cancer Commun (Lond)

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. [Abstract]

2023 Apr;43(4):435-454. PMID: 36855844
J Clin Invest

Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury. [Abstract]

2024 Oct 1;134(24):e183161. PMID: 39352872

SC-43 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]

SC-43 (10 mg/kg; oral gavage; three intermittent doses before and after LPS administration) treatment reduced alveolar neutrophils and CitH3-DNA NET complexes, while alveolar protein leakage and NE-DNA NET levels were unchanged..

SC-43 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]

Lung H&E stained tissue in DMSO control and SC43 (SC-43) (10 mg/kg; oral gavage; three intermittent doses before and after LPS administration) treated mice indicating reduced perihilar inflammation with SC43 administration.

SC-43 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]

Dose-dependent reduction in LPS-induced ROS (superoxide release) production with SC43 (SC-43) (10 mg/kg; oral gavage; three intermittent doses before and after LPS administration) versus DMSO (vehicle) control (n = 3).
Int J Surg

Inhibition of Sirpα expression enhances microglial phagocytic clearance of myelin debris and reduces neuronal PANoptosis after spinal cord injury. [Abstract]

2026 Feb 12. PMID: 41677350
J Pharm Biomed Anal

Impacts of small-molecule STAT3 inhibitor SC-43 on toxicity, global proteomics and metabolomics of HepG2 cells. [Abstract]

2024 May 15:242:116023. PMID: 38395000

SC-43 purchased from MedChemExpress. Usage Cited in: J Pharm Biomed Anal. 2024 May 15:242:116023. [Abstract]

Effect of SC-43 with various concentrations on the cell viability at various time points. Cells were treated with SC-43 (0.78-100 μM) at various concentrations for 2 h、4 h、8 h、12 h and 24 h. Cell viability was determined by the Cell Counting Kit-8.

SC-43 purchased from MedChemExpress. Usage Cited in: J Pharm Biomed Anal. 2024 May 15:242:116023. [Abstract]

Effect of SC-43 with different concentrations on the RPA1 and TAP1 protein levels in HepG2 cells. Cells were treated with SC-43 (3.125-25 μM) at various concentrations for 2 h. The protein level was determined by the ELISA kit.
bioRxiv

Loss of neutrophil Shp1 produces hemorrhagic and lethal acute lung injury. [Abstract]

2024 May 28:2024.05.23.595575. PMID: 38854059

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (578.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3159 mL

11.5794 mL

23.1589 mL

5 mM

0.4632 mL

2.3159 mL

4.6318 mL

10 mM

0.2316 mL

1.1579 mL

2.3159 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089. [Content Brief]

[2]. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3159 mL	11.5794 mL	23.1589 mL	57.8972 mL
	5 mM	0.4632 mL	2.3159 mL	4.6318 mL	11.5794 mL
	10 mM	0.2316 mL	1.1579 mL	2.3159 mL	5.7897 mL
	15 mM	0.1544 mL	0.7720 mL	1.5439 mL	3.8598 mL
	20 mM	0.1158 mL	0.5790 mL	1.1579 mL	2.8949 mL
	25 mM	0.0926 mL	0.4632 mL	0.9264 mL	2.3159 mL
	30 mM	0.0772 mL	0.3860 mL	0.7720 mL	1.9299 mL
	40 mM	0.0579 mL	0.2895 mL	0.5790 mL	1.4474 mL
	50 mM	0.0463 mL	0.2316 mL	0.4632 mL	1.1579 mL
	60 mM	0.0386 mL	0.1930 mL	0.3860 mL	0.9650 mL
	80 mM	0.0289 mL	0.1447 mL	0.2895 mL	0.7237 mL
	100 mM	0.0232 mL	0.1158 mL	0.2316 mL	0.5790 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SC-43

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) SC-43

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SC-43 Related Classifications

HY-136657 Related Classifications